Table 2.
Data from the American College of Rheumatology’s Rheumatoid Arthritis Quality Measures Project Expert Panel Rating Process for face validity and feasibility, by measure.1,2
| Measures | Median score for validity | Median score for feasibility | # of raters with validity score ≤ 3 | # of raters with validity score ≥ 7 | # of raters total | % of raters with score ≤ 3 |
|---|---|---|---|---|---|---|
| Rheumatoid Arthritis: Assessment of Disease Activity | 9 | 7 | 1 | 11 | 14 | 7.14% |
| Rheumatoid Arthritis: Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | 9 | 8 | 1 | 13 | 14 | 7.14% |
| Rheumatoid Arthritis: Functional Status Assessment | 8 | 8 | 1 | 11 | 14 | 7.14% |
| Rheumatoid Arthritis: Tuberculosis screening | 9 | 8.5 | 0 | 14 | 14 | 0% |
1
Panelists were provided with the following instructions: “Your validity ratings should reflect whether you believe that the measure can be used to reflect the quality of care for RA. Questions to consider in determining your validity ratings should include:
- Is there adequate scientific evidence or professional consensus to support the indicator?
- Are there identifiable health benefits to patients who receive care specified by the indicator?
- Based on your professional experience, would you consider providers with significantly higher rates of adherence to the indicator higher quality providers?
- Are the majority of factors that determine adherence to the indicator under the control of the physician or health care system?”
2
Measure scale definitions: For validity, 1=definitely NOT valid to 9=definitely valid; for feasibility, 1=definitely NOT feasible; 9=definitely feasible.